Evidence map›Paper›PMID 34876436›Full record

ArticleBMJ open2021

Observing time effect of SSRIs on suicide risk and suicide-related behaviour: a network meta-analysis protocol.

Qing-Hua Chen, Yu-Ling Li, Yi-Ru Hu, Wan-Yuan Liang, Bin Zhang

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Qing-Hua Chen *Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Yu-Ling Li *Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Yi-Ru HuAffiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Wan-Yuan LiangAffiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Bin ZhangAffiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China zhang.bin845@foxmail.com.ORCID 0000-0002-9280-8247
Guangzhou Medical University · CNGuangzhou Psychiatric Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSuicide is a serious problem worldwide and 90% cases are associated with pre-existing or underlying mental illness. As a common treatment for depressive symptoms that suicidal people may receive, selective serotonin reuptake inhibitors (SSRIs) have been linked to a possible increase in suicide rates. Studies focusing on SSRIs and suicide have produced inconsistent results, suggesting that use of SSRIs decreases, increases, has no effect on suicide rates, or that the effect of SSRIs on suicide is age-dependent. This protocol of network meta-analysis aims to precisely evaluate the time effects of SSRIs by observing weekly changes of suicidality in the first 2 months of the treatment, and consequently, to explore whether the effect of the SSRIs on suicide varies depending on the stages of the treatment; if so, we will identify the turning point. METHODS AND ANALYSIS: We will search in the following databases: PubMed, Web of science, China National Knowledge Infrastructure and Wanfang Data, from dates of inception to 9 July 2021, with language restricted to English and Chinese. Studies focusing on the time effect of SSRIs on suicide will be retrieved. Then, the study selection process will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline, and the quality assessment will be conducted with Cochrane Collaboration's tool. Two researchers will work independently on data extraction using a standardised data extraction spreadsheet. Any disagreement between two researchers will be discussed and determined by a third researcher. ETHICS AND DISSEMINATION: This work does not require ethics approval as it will be based on published studies. This review will be published in peer-reviewed journals. PROSPERO REGISTRATION NUMBER: CRD42021244779.

Indexed as

Selective Serotonin Reuptake InhibitorsSuicide PreventionDisease SusceptibilityHumansNetwork Meta-Analysis as TopicReview Literature as TopicSuicidal IdeationSelective Serotonin Reuptake Inhibitorsdepression & mood disordersprotocols & guidelinessuicide & self-harm

Identifiers

PMID34876436
PMCPMC8655524
OpenAlexW4200573198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.